title: [Treatment of depression: the current state and perspectives of the development of pharmacological studies].
abstract: A review of literature over the last two decades is presented. It is emphasized that psyachopharmacotherapy currently remains a main method of treatment of severe and moderate depression. Pharmacogenetic studies are directed mainly towards the identification of probable targets based on pharmacokinetcs and pharmacodynamics of andidepressants as well as the aspect of identification of probably predictors for treatment response.
authors.forename: N N
authors.initials: NN
authors.lastname: Ivanetz
authors.forename: Yu G
authors.initials: YG
authors.lastname: Tikhonova
authors.forename: M A
authors.initials: MA
authors.lastname: Kinkulkina
authors.forename: T I
authors.initials: TI
authors.lastname: Avdeeva
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism; D000928:Antidepressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D012701:Serotonin / Q000378:metabolism
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000928:Antidepressive Agents; D012701:Serotonin; D003577:Cytochrome P-450 Enzyme System